Ratio Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Ratio Therapeutics's estimated annual revenue is currently $6.1M per year.
- Ratio Therapeutics's estimated revenue per employee is $105,698
- Ratio Therapeutics's total funding is $95M.
Employee Data
- Ratio Therapeutics has 58 Employees.
- Ratio Therapeutics grew their employee count by 32% last year.
Ratio Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman, CEO | Reveal Email/Phone |
2 | Chief Legal Officer & General Counsel | Reveal Email/Phone |
3 | CFO and COO | Reveal Email/Phone |
4 | Chief Data Officer | Reveal Email/Phone |
5 | Director, President, Chief Scientific Officer | Reveal Email/Phone |
6 | Chief Technology Officer | Reveal Email/Phone |
7 | Chief Operating Officer | Reveal Email/Phone |
8 | Head Biology | Reveal Email/Phone |
9 | Head Medical Physics | Reveal Email/Phone |
10 | Head Discovery | Reveal Email/Phone |
Ratio Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 340 | 0% | $634M | N/A |
#2 | $57.9M | 288 | 0% | N/A | N/A |
#3 | $2M | 10 | -17% | N/A | N/A |
#4 | $33.6M | 167 | 20% | N/A | N/A |
#5 | $15.5M | 77 | 126% | N/A | N/A |
#6 | $25.1M | 125 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.1M | 50 | -2% | N/A | N/A |
#9 | $1.8M | 385 | -4% | $538M | N/A |
#10 | $46.6M | 232 | -7% | N/A | N/A |
What Is Ratio Therapeutics?
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie \theranostics\. The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
keywords:N/A
$95M
Total Funding
58
Number of Employees
$6.1M
Revenue (est)
32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.7M | 58 | -15% | N/A |
#2 | $8.9M | 58 | N/A | N/A |
#3 | $4.6M | 58 | 18% | $23M |
#4 | $11.8M | 58 | -8% | N/A |
#5 | $7.9M | 58 | 9% | N/A |